Metastatic Advanced Pancreas Sorafenib

Inclusion Criteria: * Signed written informed consent prior to beginning protocol specific procedures * Male or female 18 to 75 years of age * Diagnosis of histologically confirmed adenocarcinoma of the pancreas * Locally advanced (non-resectable) or metastatic pancreatic cancer * Presence of at least one uni-dimensional indicator lesion measurable by CT scan or MRI in not an irradiated area (RECIST criteria) * Karnofsky performance status of ≥ 70 at study entry * Neutrophils ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL * Bilirubin level either normal or \< 1.5 x ULN * ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present) * Serum creatinine \< 1.5 x ULN * Amylase and lipase ≤ 1.5 x the upper limit of normal * PT or INR and PTT \< 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists). * Effective contraception for both male and female patients if the risk of conception exists Exclusion Criteria: * Brain metastases * Previous chemotherapy for locally advanced or metastatic pancreatic cancer. * Adjuvant therapy if documented recurrence is within 6 months after the end of adjuvant treatment) * Radiotherapy within 4 weeks prior to study entry * Major surgery within 4 weeks of first dose of study drug * Concurrent chronic systemic immune therapy * Any investigational agent(s) 4 weeks prior to entry * Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 6 months * Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months * Acute or subacute intestinal occlusion or history of inflammatory bowel disease * Known grade 3 or 4 allergic reaction to any of the components of the treatment * Known drug abuse/ alcohol abuse * Legal incapacity or limited legal capacity * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent * Women who are pregnant or breastfeeding * Acute or subacute intestinal occlusion * Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial).